Cingulate Inc. Notes Payable
Cingulate Inc. (CING) had Notes Payable of $2.10 million as of 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Balance Sheet › Liabilities
us-gaap:NotesPayable · last filed 2024-04-01
- 2023-12-31: Notes Payable $2.10M.
- 2023-09-30: Notes Payable $2.10M.
- 2023-05-09: Notes Payable $3.00M.
- 2020-12-31: Notes Payable $500.33K.
| Period end | Notes Payable |
|---|---|
| 2023-12-31 | $2.10M 10-K · filed 2024-04-01 |
| 2023-09-30 | $2.10M 10-Q · filed 2023-11-13 |
| 2023-05-09 | $3.00M 10-Q · filed 2023-08-14 |
| 2020-12-31 | $500.33K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |